

Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from May 2015

For further details see *PACE Bulletin* Volume 9 No 9 (June 2015)

| Drug | Indication(s) | Traffic Light and <i>Joint Formulary</i> Status |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Empagliflozin tablets 10mg and 25mg (Jardiance) (Boehringer Ingelheim) | For type 2 diabetes inadequately controlled by diet and exercise in combination with other hypo-glycaemics. | GREEN. Included in the Lincolnshire Joint Formulary. |
| Empagliflozin tablets 10mg and 25mg (Jardiance) (Boehringer Ingelheim) | For use as monotherapy for the treatment of type 2 diabetes inadequately controlled by diet and exercise when metformin is not tolerated. | RED-RED. Not approved for use through the Lincolnshire Joint Formulary for this indication. |
| Glycopyrronium bromide 2% roll on applicator (unlicensed special) | For the treatment of palmar hyperhidrosis that has failed to respond to oral therapy and iontophoresis. | AMBER without shared care (single patient request) |
| Icaps – various Eye Vitamin formulations including Lutein and Omega-3 Formula, AREDS Formula, Multivitamin Formula and Lutein and Zeaxanthin Formula (Alcon) | Health food supplements marketed as aids to the improvement of eye health | RED-RED not approved for inclusion in the Lincolnshire Joint Formulary. Should not be prescribed on the NHS for the prevention of age-related macular degeneration. |
| Insulin degludec 100 iu/liraglutide 3.6mg injection (Xultophy) (Novo Nordisk) | For the treatment of adults with type 2 diabetes to improve glycaemic control in combination with oral glucose lowering medicines when these alone or combined with basal insulin do not provide adequate glycaemic control. | RED-RED not approved for inclusion in the Lincolnshire Joint Formulary. |
| Macushield Lutein, Zeaxanthin, and Meso-zeaxanthin Capsules, and MacuShield Gold Capsules (Macuvision) | Health food supplements marketed as aids to the improvement of eye health | RED-RED not approved for inclusion in the Lincolnshire Joint Formulary. Should not be prescribed on the NHS for the prevention of age-related macular degeneration. |
| Occuvite Complete Capsules (Bausch and Lomb) | Health food supplements marketed as aids to the improvement of eye health | RED-RED not approved for inclusion in the Lincolnshire Joint Formulary. Should not be prescribed on the NHS for the prevention of age-related macular degeneration. |
| Preservision Eye Vitamin and Mineral Food Supplement capsules (Original) (Bausch and Lomb) | Health food supplements marketed as aids to the improvement of eye health | RED-RED not approved for inclusion in the Lincolnshire Joint Formulary. Should not be prescribed on the NHS for the prevention of age-related macular degeneration. |

| | | |
|----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Preservision Eye Vitamin and Mineral Food Supplement capsules (Lutein) (Bausch and Lomb) | Health food supplements marketed as aids to the improvement of eye health | RED-RED not approved for inclusion in the Lincolnshire Joint Formulary. Should not be prescribed on the NHS for the prevention of age-related macular degeneration. |
| Rifaximin tablets 550mg (Targaxan) (Norgine) | For the reduction in recurrence of overt hepatic encephalopathy | AMBER Included in the <i>Lincolnshire Joint Formulary</i> for this indication |
| Rifaximin tablets 200mg (Xifaxanta) (Norgine) | For non-invasive traveller's diarrhoea | RED-RED Not approved for the Lincolnshire Joint Formulary for this indication |
| Viteyes AREDS 2 Advanced Antioxidant Vitamins plus Zinc, Lutein and Zeaxanthin capsules (Vitamin Health) | Health food supplements marketed as aids to the improvement of eye health | RED-RED not approved for inclusion in the Lincolnshire Joint Formulary. Should not be prescribed on the NHS for the prevention of age-related macular degeneration. |
| Viteyes 2 plus Omega-3 Softgels | Health food supplements marketed as aids to the improvement of eye health | RED-RED not approved for inclusion in the Lincolnshire Joint Formulary. Should not be prescribed on the NHS for the prevention of age-related macular degeneration. |
| Visionace Original tablets (Vitabiotics) | Health food supplements marketed as aids to the improvement of eye health | RED-RED not approved for inclusion in the Lincolnshire Joint Formulary. Should not be prescribed on the NHS for the prevention of age-related macular degeneration. |
| Visionace Plus Omega 3 tablets (Vitabiotics) | Health food supplements marketed as aids to the improvement of eye health | RED-RED not approved for inclusion in the Lincolnshire Joint Formulary. Should not be prescribed on the NHS for the prevention of age-related macular degeneration. |
| | | |

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP

responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care.**

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@gemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION